Article Text

Download PDFPDF
Incurable, but treatable: how to address challenges for an emerging group

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Competing interests None declared.

  • Provenance and peer review Not commissioned; internally peer reviewed.

  • i Research undertaken by Monitor Deloitte, commissioned by Macmillan Cancer Support. An extensive review identified ‘best available’ data from different care settings and perspectives. No single source provides definitive data on the prevalence of LTCs amongst the UK public and people living with cancer. UK-wide estimates in this document are therefore derived from the following ‘best available’ sources to estimate the population living with with cancer and another long term condition:

    ▸ Patient-reported data from Health Survey England and Scottish Health Survey, 2012

    ▸ Primary care data from Quality and Outcomes Framework (QOF) summary records, 2012–13

    ▸ Secondary care data from Hospital Episode Statistics, 2003–12

    To be considered long-term for the purposes of this analysis, a condition had to satisfy the following criteria. It must:

    ▸ Be a symptom or morbidity, and;

    ▸ Prevent the individual leading a ‘normal’ life, by being:

      – A chronic condition where there is a need for active management, or;

      – An acute condition leading to residual disability, and;

    ▸ Last longer than one year, and;

    ▸ Have been recorded:

      – At any time during the patient's life, or;

      – Between three years pre-cancer diagnosis and seven years post-cancer diagnosis for LTCs being actively treated within secondary care during cancer survivorship

    We assume that these data sources are representative of the rest of the UK and apply the proportion of LTCs in the cancer population by age to total cancer prevalence figures to derive our estimate of 1.8 million for 2015 and future projections. See executive summary for more details of the sources and analysis.